non-responders showed longer disease duration, higher BMI and elevated ESR/CRP. Prodrug diacerein is converted into its active form rhein within the skin, thereby allowing for improved skin wound healing.

Erythrocyte sedimentation rate was significantly elevated in MTX non-responders, compared to CsA responders. The clinical and laboratory information was retrospectively reviewed. Total visit were significantly longer in MTX responders, compared to in CsA responders. The patients were divided into four subgroups including CsA responders, MTX responders, CsA non-responders, whose CsA were switched to MTX, and MTX non-responders, whose MTX were switched to CsA. The clinical and laboratory information was retrospectively reviewed. Total 488 patients with psoriasis vulgaris were enrolled, including 199 CsA responders, 199 MTX responders, 53 CsA non-responders, 37 MTX non-responders. Disease durations before initial visit were significantly longer in MTX responders, compared to in CsA responders (80.3±7.3 vs. 45.1±5.8 months, p<0.05). Also, either CsA or MTX non-responders had significantly longer disease duration than either CsA or MTX responders (102.0±7.12 vs. 87.3±4.83 months, p=0.04). Body mass index was significantly higher in CsA non-responders, compared to in CsA responders (22.15±0.71 vs. 23.6±0.50 [kg/m²], p=0.04).

Erythrocyte sedimentation rate was significantly elevated in MTX non-responders, compared to in MTX responders (17.7±0.34 vs. 11.3±0.38 [mm/hour], p=0.02). In addition, either CsA or MTX non-responders showed significantly elevated ESR than either CsA or MTX responders (15.46±2.21 vs. 10.75±0.68 [mm/hour], p=0.03). This data showed CsA or MTX non-responders showed longer disease duration, higher BMI and elevated ESR/CRP.

Clinical characteristics according to therapeutic efficacy of cyclosporine or methotrexate in patients with psoriasis vulgaris

Psoriasis vulgaris is a chronic, multifactorial, inflammatory skin disease. Either cyclosporine (CsA) or methotrexate (MTX) is regarded as most commonly used systemic drugs for the treatment of moderate to severe psoriasis. However, there is no sufficient information related with clinical and laboratory characteristics of patients, which might have an influence on the therapeutic efficacy. The goal of this study was to compare clinical and laboratory manifestations among the psoriatic patients treated with either CsA or MTX. Patients with psoriasis vulgaris, who had been treated with either CsA or MTX at the dermatologic clinic of Ajou University Hospital from January 2012 to December 2016, were enrolled. The patients were divided into four subgroups including CsA responders, MTX responders, CsA non-responders, whose CsA were switched to MTX, and MTX non-responders, whose MTX were switched to CsA. The clinical and laboratory information was retrospectively reviewed. Total 488 patients with psoriasis vulgaris were enrolled, including 199 CsA responders, 199 MTX responders, 53 CsA non-responders, 37 MTX non-responders. Disease durations before initial visit were significantly longer in MTX responders, compared to in CsA responders (80.3±7.3 vs. 45.1±5.8 months, p<0.05). Also, either CsA or MTX non-responders had significantly longer disease duration than either CsA or MTX responders (102.0±7.12 vs. 87.3±4.83 months, p=0.04). Body mass index was significantly higher in CsA non-responders, compared to in CsA responders (22.15±0.71 vs. 23.6±0.50 [kg/m²], p=0.04).

Erythrocyte sedimentation rate was significantly elevated in MTX non-responders, compared to in MTX responders (17.7±0.34 vs. 11.3±0.38 [mm/hour], p=0.02). In addition, either CsA or MTX non-responders showed significantly elevated ESR than either CsA or MTX responders (15.46±2.21 vs. 10.75±0.68 [mm/hour], p=0.03). This data showed CsA or MTX non-responders showed longer disease duration, higher BMI and elevated ESR/CRP.

Surgical wound healing in patients with epidermolysis bullosa

A Harris and D Murrell University of New South Wales, Newcastle, NSW, Australia

Despite limited evidence to suggest patients with Epidermolysis Bullosa (EB) have more postoperative wound complications than the general population, we have noted reluctance among some surgeons to operate on these patients. Patients recruited from the Australian National Diagnostical Laboratory Database for EB and the Australasian EB Registry were posted the ‘Surgical Wound and Scar Healing in EB’ questionnaire which contains twenty-two questions about a patients experience of having surgery. Forty-six patients reported a total of 94 surgical procedures. The most frequent surgical procedure was the excision of a skin lesion, followed by musculoskeletal surgery, a caesarean section or an appendectomy. Five patients reported blistering at the surgical wound site after seven surgeries. Four patients reported four postoperative wound infections and one reported a postoperative wound dehiscence. Twenty patients had 34 postoperative wounds which they felt healed slower than someone without EB and 30 patients had 55 postoperative wounds which they healed at the same rate as someone without EB. After 67 surgeries, the postoperative scar was reported to heal flat and after 18 it was reported to heal as a keloid scar. It is unlikely that patients with localised EB simplex will develop blistering at the postoperative wound site, but about a quarter of patients with generalised EB may develop blistering which is likely to interfere with wound healing. Postoperative wound infections do not appear to occur any more frequently in patients with EB than in patients within the general population and wound dehiscence is uncommon in patients with EB. Postoperative wounds may heal at a similar or slower rate in patients with EB compared to those within the general population and patients with EB may have a propensity to develop keloid scars. Despite the inherent limitations of a postal survey we feel clinicians should be more confident to refer patients with EB for surgery and surgeons reassured about postoperative wound healing and complications.

Experiences with Smo antagonist vismodegib for the treatment of locally advanced basal cell carcinoma

A Banvolgyi, K Lorincz, N Kiss, N Gyongyosi, D Marton and NM Wikonkal

Dermatology, Semmelweis University, Budapest, Hungary

Basal cell carcinoma (BCC) is the most common skin tumor. Although surgical excision is considered standard treatment, locally invasive advanced BCCs are difficult to treat. Gorlin-Goltz syndrome is an inherited disorder which is characterized by the occurrence of multiple BCC-s. Vismodegib (Erivedge, Roche) is the first Smo inhibitor agent which is approved by the FDA for the treatment of advanced BCC, with overlapping characteristics. However, respective evidence is rare and data on risk factors for periodontitis in psoriasis patients are minimal. The aim of this study was to expand the evidence of psoriasis-associated periodontitis and establish a potential risk profile for periodontitis. The data analyzed in this study were collected at the Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany. Periodontitis and psoriasis are suggested to be co-occurring, chronic inflammatory conditions with overlapping characteristics. However, respective evidence is rare and data on risk factors for periodontitis in psoriasis patients are minimal. The aim of this study was to expand the evidence of psoriasis-associated periodontitis and establish a potential risk profile for periodontitis. The data analyzed in this study were collected at the Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

The prevalence of periodontitis is increased in psoriasis and linked to its inverse subtype

C Pains 1, 2, A Hirtenthaler 1, 3, 4, K Lorincz 1, 3, 4, N Kiss 1, 3, 4, N Gyongyosi 1, 3, 4, D Marton 2 and NM Wikonkal 1

1 Dermatology, State Hospital Klagenfurt a. W., Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany

Periodontitis and psoriasis are suggested to be co-occurring, chronic inflammatory conditions with overlapping characteristics. However, respective evidence is rare and data on risk factors for periodontitis in psoriasis patients are minimal. The aim of this study was to expand the evidence of psoriasis-associated periodontitis and establish a potential risk profile for periodontitis. The data analyzed in this study were collected at the Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

The prevalence of periodontitis is increased in psoriasis and linked to its inverse subtype

C Pains 1, 2, A Hirtenthaler 1, 3, 4, K Lorincz 1, 3, 4, N Kiss 1, 3, 4, N Gyongyosi 1, 3, 4, D Marton 2 and NM Wikonkal 1

1 Dermatology, State Hospital Klagenfurt a. W., Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany

Periodontitis and psoriasis are suggested to be co-occurring, chronic inflammatory conditions with overlapping characteristics. However, respective evidence is rare and data on risk factors for periodontitis in psoriasis patients are minimal. The aim of this study was to expand the evidence of psoriasis-associated periodontitis and establish a potential risk profile for periodontitis. The data analyzed in this study were collected at the Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

The prevalence of periodontitis is increased in psoriasis and linked to its inverse subtype

C Pains 1, 2, A Hirtenthaler 1, 3, 4, K Lorincz 1, 3, 4, N Kiss 1, 3, 4, N Gyongyosi 1, 3, 4, D Marton 2 and NM Wikonkal 1

1 Dermatology, State Hospital Klagenfurt a. W., Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

The prevalence of periodontitis is increased in psoriasis and linked to its inverse subtype

C Pains 1, 2, A Hirtenthaler 1, 3, 4, K Lorincz 1, 3, 4, N Kiss 1, 3, 4, N Gyongyosi 1, 3, 4, D Marton 2 and NM Wikonkal 1

1 Dermatology, State Hospital Klagenfurt a. W., Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

The prevalence of periodontitis is increased in psoriasis and linked to its inverse subtype

C Pains 1, 2, A Hirtenthaler 1, 3, 4, K Lorincz 1, 3, 4, N Kiss 1, 3, 4, N Gyongyosi 1, 3, 4, D Marton 2 and NM Wikonkal 1

1 Dermatology, State Hospital Klagenfurt a. W., Klagenfurt, Austria, 2 Dermatology, Medical University of Graz, Graz, Austria and 3 Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.